sumatriptan has been researched along with Disease Models, Animal in 59 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lasmiditan and sumatriptan significantly increased post-stroke seizure thresholds in mice by suppressing inflammatory cytokines and neuronal apoptosis." | 8.12 | Neuroprotective effects of Lasmiditan and Sumatriptan in an experimental model of post-stroke seizure in mice: Higher effects with concurrent opioid receptors or K ( Amanlou, A; Dehpour, AR; Ejtemaei-Mehr, S; Eslami, F; Ghasemi, M; Rahimi, N; Rashidian, A; Shayan, M; Solaimanian, S, 2022) |
| " The aim of these studies was to evaluate the effects of the 5-HT(1B/1D) receptor agonist sumatriptan in specific models of pain states: a mouse model of inflammation-induced thermal hyperalgesia and a rat model of nerve injury-induced thermal hyperalgesia." | 7.71 | Inhibition of inflammation-induced thermal hypersensitivity by sumatriptan through activation of 5-HT(1B/1D) receptors. ( Bingham, S; Davey, PT; Overend, P; Parsons, AA; Raval, P; Sammons, M, 2001) |
| " Acute administration of l-NAME, a non-specific inhibitor of nitric oxide synthase, along with sumatriptan attenuated the anti-allergic effects of sumatriptan but chronic administration of l-NAME did not affect the influences of sumatriptan." | 5.51 | Inhibition of ovalbumin-induced allergic rhinitis by sumatriptan through the nitric oxide pathway in mice. ( Alaeddini, M; Dabiri, S; Dehpour, AR; Etemad-Moghadam, S; Hemmati, S; Rahimi, N, 2019) |
| "Lasmiditan and sumatriptan significantly increased post-stroke seizure thresholds in mice by suppressing inflammatory cytokines and neuronal apoptosis." | 4.12 | Neuroprotective effects of Lasmiditan and Sumatriptan in an experimental model of post-stroke seizure in mice: Higher effects with concurrent opioid receptors or K ( Amanlou, A; Dehpour, AR; Ejtemaei-Mehr, S; Eslami, F; Ghasemi, M; Rahimi, N; Rashidian, A; Shayan, M; Solaimanian, S, 2022) |
| "Sprague Dawley rats were administered six doses of lasmiditan (10 mg/kg), sumatriptan (10 mg/kg), or sterile water orally over 2 weeks and cutaneous allodynia was evaluated regularly in the periorbital and hindpaw regions using von Frey filaments." | 3.96 | Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache. ( Aurora, SK; Dodick, DW; Johnson, KW; Navratilova, E; Oyarzo, J; Porreca, F; Rau, JC; Schwedt, TJ, 2020) |
| "Sumatriptan elicited cutaneous allodynia in both cephalic and hindpaw regions; cutaneous allodynia resolved to baseline levels after cessation of drug administration (14 days)." | 3.96 | Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. ( Banerjee, P; Behravesh, S; Dodick, DW; Navratilova, E; Oyarzo, J; Porreca, F, 2020) |
| " Methods We assessed in rats the roles of dose and repeat administration of systemic isosorbide dinitrate (ISDN), a nitric oxide donor, on the occurrence and development of cephalic/face and extracephalic/hindpaw mechanical allodynia as a surrogate of migraine pain, and the effect of acute systemic sumatriptan and olcegepant and chronic systemic propranolol on these behavioral changes." | 3.88 | Recurrent administration of the nitric oxide donor, isosorbide dinitrate, induces a persistent cephalic cutaneous hypersensitivity: A model for migraine progression. ( Dallel, R; Descheemaeker, A; Luccarini, P, 2018) |
| " Results VL-102-evoked acute and chronic mechanical cephalic and hind-paw allodynia in a dose-dependent manner, which was blocked by the migraine medications sumatriptan, propranolol, and topiramate." | 3.88 | Soluble guanylyl cyclase is a critical regulator of migraine-associated pain. ( Ben Aissa, M; Bennett, BM; Bertels, Z; Gaisina, IN; Gandhi, R; Lee, SH; Litosh, V; Moye, LS; Novack, M; Pradhan, AA; Thatcher, GR; Tipton, AF; Wang, Y, 2018) |
| " This project investigates the safety and effectiveness of pulsed focused ultrasound (FUS) in a validated rodent headache model of cutaneous allodynia associated with chronic migraine (CM) as compared to sumatriptan and ablative lesioning." | 3.88 | The use of focused ultrasound for the treatment of cutaneous allodynia associated with chronic migraine. ( Burdette, C; Frith, L; Gannon, S; Gee, L; Ghoshal, G; Hellman, A; Kaszuba, B; Kumar, V; Maietta, T; Neubauer, P; Panse, D; Pilitsis, JG; Qian, J; Shin, DS; Walling, I; Williams, E, 2018) |
| "Ipsilateral, but not contralateral, pre-treatment (in μg/paw) with sumatriptan (10-300), methysergide (1-30) or dihydroergotamine (1-30) significantly prevented flinching behavior (at 1h) as well as secondary allodynia and hyperalgesia (at day 6) induced by formalin." | 3.79 | Role of 5-HT₁B/₁D receptors in the reduction of formalin-induced nociception and secondary allodynia/hyperalgesia produced by antimigraine drugs in rats. ( Argüelles, CF; Godínez-Chaparro, B; Granados-Soto, V; López-Santillán, FJ; Villalón, CM, 2013) |
| " The aim of these studies was to evaluate the effects of the 5-HT(1B/1D) receptor agonist sumatriptan in specific models of pain states: a mouse model of inflammation-induced thermal hyperalgesia and a rat model of nerve injury-induced thermal hyperalgesia." | 3.71 | Inhibition of inflammation-induced thermal hypersensitivity by sumatriptan through activation of 5-HT(1B/1D) receptors. ( Bingham, S; Davey, PT; Overend, P; Parsons, AA; Raval, P; Sammons, M, 2001) |
| "Migraine is number seven in WHO's list of all diseases causing disability and the third most costly neurological disorder in Europe." | 2.49 | Animal migraine models for drug development: status and future perspectives. ( Jansen-Olesen, I; Olesen, J; Tfelt-Hansen, P, 2013) |
| "infusion of 5-HT can abort migraine." | 2.42 | Migraine: pathophysiology, pharmacology, treatment and future trends. ( Centurión, D; de Vries, P; Saxena, PR; Valdivia, LF; Villalón, CM, 2003) |
| "We believe that the use of these migraine models will provide even better treatment for migraine patients in the next millennium." | 2.40 | Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. ( De Vries, P; Saxena, PR; Villalón, CM, 1999) |
| "Pretreatment with propranolol or nor-BNI prior to restraint stress prevented both transient cutaneous allodynia and priming, demonstrated by a lack of umbellulone-induced cutaneous allodynia." | 1.62 | A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain. ( Chessell, IP; Dodick, DW; Kopruszinski, CM; Navratilova, E; Porreca, F; Swiokla, J, 2021) |
| " Acute administration of l-NAME, a non-specific inhibitor of nitric oxide synthase, along with sumatriptan attenuated the anti-allergic effects of sumatriptan but chronic administration of l-NAME did not affect the influences of sumatriptan." | 1.51 | Inhibition of ovalbumin-induced allergic rhinitis by sumatriptan through the nitric oxide pathway in mice. ( Alaeddini, M; Dabiri, S; Dehpour, AR; Etemad-Moghadam, S; Hemmati, S; Rahimi, N, 2019) |
| "Chloroquine was injected intradermally into the rostral back of NMRI mice, and the scratching behavior was evaluated by measuring the number of bouts over 30 min." | 1.48 | Pharmacological evidence of involvement of nitric oxide pathway in anti-pruritic effects of sumatriptan in chloroquine-induced scratching in mice. ( Afshari, K; Dehpour, AR; Foroutan, A; Haddadi, NS; Ostadhadi, S; Rahimi, N; Shakiba, S, 2018) |
| "Sumatriptan, an acute migraine treatment blocked acute blood flow changes in response to TRPA1 or transient receptor potential vanilloid receptor-1 agonists." | 1.48 | Induction of chronic migraine phenotypes in a rat model after environmental irritant exposure. ( Hurley, JH; Johnson, PL; Kunkler, PE; Oxford, GS; Zhang, L, 2018) |
| "Curcumin has antioxidative properties that could be useful in various diseases due to its ability to act on multiple targets of various cellular pathways." | 1.48 | The effect of intravenous administration of liposomal curcumin in addition to sumatriptan treatment in an experimental migraine model in rats. ( Bolboacă, SD; Bulboacă, AC; Bulboacă, AE; Porfire, A; Sfrângeu, CA; Stănescu, IC; Tefas, L, 2018) |
| "Sumatriptan, which is an anti-migraine agent is a specific agonist for 5-hydroxytryptamine 1B, 1D (5HT1B, 1D) receptors." | 1.48 | The protective effects of sumatriptan on vincristine - induced peripheral neuropathy in a rat model. ( Abdollahi, A; Afshari, K; Dehpour, AR; Hadian, MR; Khalilzadeh, M; Momeny, M; Norouzi-Javidan, A; Panahi, G; Rahimi, N; Rashidian, A; Shakiba, S, 2018) |
| "Characterization of headache and pain related behaviours included assessment of cutaneous tactile pain sensitivity, using von Frey monofilaments, and ongoing pain using the conditioned place preference or aversion (CPP/CPA) paradigms." | 1.48 | Development of CGRP-dependent pain and headache related behaviours in a rat model of concussion: Implications for mechanisms of post-traumatic headache. ( Bree, D; Levy, D, 2018) |
| "The development of new anti-migraine treatments is limited by the difficulty inassessing migraine pain in laboratory animals." | 1.46 | Depression of home cage wheel running: a reliable and clinically relevant method to assess migraine pain in rats. ( Kandasamy, R; Lee, AT; Morgan, MM, 2017) |
| "Background The development of novel migraine therapies has been slow, in part because of the small number of clinically relevant animal models." | 1.43 | The effects of acute and preventive migraine therapies in a mouse model of chronic migraine. ( Charles, A; McGuire, B; Pradhan, AA; Tarash, I; Tipton, AF, 2016) |
| "Trigeminal allodynia and photosensitivity were measured." | 1.43 | Trigeminal Pain Molecules, Allodynia, and Photosensitivity Are Pharmacologically and Genetically Modulated in a Model of Traumatic Brain Injury. ( Clark, SW; Daiutolo, BV; Elliott, MB; Tyburski, A, 2016) |
| "We reported that hyperalgesia induced by intradermal GTN has a delay to onset of ∼ 30 min in male and ∼ 45 min in female rats." | 1.43 | Mechanisms mediating nitroglycerin-induced delayed-onset hyperalgesia in the rat. ( Ferrari, LF; Green, PG; Levine, JD, 2016) |
| "Many migraineurs also display alterations in blink reflexes, known to involve brainstem circuits." | 1.43 | Pharmacology of reflex blinks in the rat: a novel model for headache research. ( Andreou, AP; Jones, MG; McMahon, SB; Spanswick, D, 2016) |
| "Sumatriptan (Imigran) is a potent and highly selective 5-HT1 receptor agonist often used in treating acute migraine." | 1.42 | Effects of sumatriptan nasal spray (Imigran) on isolated rat's tracheal smooth muscle. ( Chang, YN; Cheng, LH; Chiu, FS; Chu, YH; Liu, SC; Wang, HW; Wu, PC, 2015) |
| "Levetiracetam is an antiepileptic drug with analgesic efficacy shown in pain models and small clinical trials." | 1.42 | The effects of levetiracetam, sumatriptan, and caffeine in a rat model of trigeminal pain: interactions in 2-component combinations. ( Micov, AM; Pecikoza, UB; Popović, BV; Stepanović-Petrović, RM; Tomić, MA, 2015) |
| "Chronic migraine is a disabling condition that affects hundreds of millions of individuals worldwide." | 1.40 | Characterization of a novel model of chronic migraine. ( Charles, A; Evans, CJ; McGuire, B; Pradhan, AA; Smith, ML; Tarash, I, 2014) |
| "Sumatriptan or saline was delivered subcutaneously by osmotic minipump for six days to Sprague-Dawley rats." | 1.40 | Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache. ( De Felice, M; Dodick, D; Green, AL; Gu, P; Ossipov, MH; Porreca, F, 2014) |
| "Sumatriptan was not able to reverse either the kainic acid-induced or the NMDA-induced hyperalgesia." | 1.32 | Indomethacin, alone and combined with prochlorperazine and caffeine, but not sumatriptan, abolishes peripheral and central sensitization in in vivo models of migraine. ( Galeotti, N; Ghelardini, C; Grazioli, I; Uslenghi, C, 2004) |
| "Sumatriptan was subcutaneously (s." | 1.32 | Effect of sumatriptan in different models of pain in rats. ( Bertolini, A; Ferrari, A; Ferraris, E; Giuliani, D; Mioni, C; Ottani, A; Sternieri, E, 2004) |
| "In an experimental migraine model, it has been shown that electrical stimulation of the rat trigeminal ganglion induced an increase in the lengths of CGRP-immunoreactive axons, increased size and number of pleomorphic axonal varicosities in the dura mater, and an increased number of c-jun and c-fos protein-expressing nerve cells in the trigeminal complex." | 1.31 | Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model. ( Chadaide, Z; Csillik, AE; Knyihár-Csillik, E; Mihály, A; Tajti, J; Vécsei, L, 2000) |
| "The effects of classical and new anti-migraine drugs such as acetylsalicylic acid (ASA), sumatriptan and the new high efficacy 5-HT1B/1D agonist donitriptan (4-[4-[2-(2-aminoethyl)-1H-indol-5-yloxyl]acetyl]piperazinyl-1-yl]benzonitrile) were evaluated in comparison with the established model of neurogenic inflammation in the meninges." | 1.31 | An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. ( Diener, HC; Guehring, H; Katsarava, Z; Liedert, B; Limmroth, V; Michel, MC; Schmitz, K, 2001) |
| "The neurogenic inflammation theory of migraine pain proposes that substance P, acting through NK-1 receptors, causes dural inflammation which enhances migraine pain." | 1.30 | The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs. ( Hipskind, PA; Johnson, KW; Lobb, KL; Nixon, JA; Phebus, LA; Stengel, PW, 1997) |
| "Naratriptan has high affinity for human recombinant 5HT1B and 5HT1D receptors (pKi = 8." | 1.30 | Naratriptan: biological profile in animal models relevant to migraine. ( Beattie, DT; Connor, HE; Feniuk, W; Humphrey, PP; North, PC; Oxford, AW; Saynor, DA, 1997) |
| "Since sumatriptan exerts its anti-migraine effect by virtue of its agonist action on 5-HT1D receptors, we suggest that sumatriptan prevents the release of CGRP from dural perivascular terminals by an action at 5-HT1D receptors." | 1.30 | Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model. ( Knyihár-Csillik, E; Samsam, M; Sáry, G; Slezák, S; Tajti, J; Vécsei, L, 1997) |
| "Sumatriptan blunted the increase in blood flow following stimulation of the trigeminal ganglion." | 1.30 | Trigeminal ganglion elicited increases in nucleus trigeminal caudalis blood flow: a novel migraine model. ( McCall, RB, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (13.56) | 18.2507 |
| 2000's | 16 (27.12) | 29.6817 |
| 2010's | 27 (45.76) | 24.3611 |
| 2020's | 8 (13.56) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Yousefi-Manesh, H | 1 |
| Shirooie, S | 1 |
| Noori, T | 1 |
| Tavangar, SM | 1 |
| Sheibani, M | 1 |
| Chaboki, A | 1 |
| Mohammadi, S | 1 |
| Dehpour, AR | 6 |
| Shayan, M | 1 |
| Eslami, F | 1 |
| Amanlou, A | 1 |
| Solaimanian, S | 1 |
| Rahimi, N | 4 |
| Rashidian, A | 2 |
| Ejtemaei-Mehr, S | 1 |
| Ghasemi, M | 1 |
| Guo, S | 2 |
| Ernstsen, C | 2 |
| Hay-Schmidt, A | 2 |
| Kristensen, DM | 2 |
| Ashina, M | 2 |
| Olesen, J | 3 |
| Christensen, SL | 2 |
| Hemmati, S | 1 |
| Dabiri, S | 1 |
| Alaeddini, M | 1 |
| Etemad-Moghadam, S | 1 |
| Liktor-Busa, E | 1 |
| Blawn, KT | 1 |
| Kellohen, KL | 1 |
| Wiese, BM | 1 |
| Verkhovsky, V | 1 |
| Wahl, J | 1 |
| Vivek, A | 1 |
| Palomino, SM | 1 |
| Davis, TP | 1 |
| Vanderah, TW | 1 |
| Largent-Milnes, TM | 1 |
| Rau, JC | 1 |
| Navratilova, E | 3 |
| Oyarzo, J | 2 |
| Johnson, KW | 2 |
| Aurora, SK | 1 |
| Schwedt, TJ | 1 |
| Dodick, DW | 3 |
| Porreca, F | 5 |
| Behravesh, S | 1 |
| Banerjee, P | 1 |
| Kopruszinski, CM | 1 |
| Swiokla, J | 1 |
| Chessell, IP | 1 |
| Dallel, R | 1 |
| Descheemaeker, A | 1 |
| Luccarini, P | 1 |
| Haddadi, NS | 2 |
| Ostadhadi, S | 2 |
| Shakiba, S | 3 |
| Afshari, K | 3 |
| Foroutan, A | 2 |
| Ben Aissa, M | 1 |
| Tipton, AF | 3 |
| Bertels, Z | 1 |
| Gandhi, R | 1 |
| Moye, LS | 2 |
| Novack, M | 1 |
| Bennett, BM | 1 |
| Wang, Y | 1 |
| Litosh, V | 1 |
| Lee, SH | 1 |
| Gaisina, IN | 1 |
| Thatcher, GR | 1 |
| Pradhan, AA | 4 |
| Kunkler, PE | 1 |
| Zhang, L | 1 |
| Johnson, PL | 1 |
| Oxford, GS | 1 |
| Hurley, JH | 1 |
| Daneshpazhooh, M | 1 |
| Bulboacă, AE | 1 |
| Bolboacă, SD | 1 |
| Stănescu, IC | 1 |
| Sfrângeu, CA | 1 |
| Porfire, A | 1 |
| Tefas, L | 1 |
| Bulboacă, AC | 1 |
| Khalilzadeh, M | 1 |
| Panahi, G | 1 |
| Hadian, MR | 1 |
| Abdollahi, A | 1 |
| Norouzi-Javidan, A | 1 |
| Momeny, M | 1 |
| Rea, BJ | 1 |
| Wattiez, AS | 1 |
| Waite, JS | 1 |
| Castonguay, WC | 1 |
| Schmidt, CM | 1 |
| Fairbanks, AM | 1 |
| Robertson, BR | 1 |
| Brown, CJ | 1 |
| Mason, BN | 1 |
| Moldovan-Loomis, MC | 1 |
| Garcia-Martinez, LF | 1 |
| Poolman, P | 1 |
| Ledolter, J | 1 |
| Kardon, RH | 1 |
| Sowers, LP | 1 |
| Russo, AF | 1 |
| Walling, I | 1 |
| Panse, D | 1 |
| Gee, L | 1 |
| Maietta, T | 1 |
| Kaszuba, B | 1 |
| Kumar, V | 1 |
| Gannon, S | 1 |
| Hellman, A | 1 |
| Neubauer, P | 1 |
| Frith, L | 1 |
| Williams, E | 1 |
| Ghoshal, G | 1 |
| Shin, DS | 1 |
| Burdette, C | 1 |
| Qian, J | 1 |
| Pilitsis, JG | 1 |
| Dripps, I | 1 |
| Sheets, Z | 1 |
| Crombie, A | 1 |
| Violin, JD | 1 |
| Godínez-Chaparro, B | 1 |
| López-Santillán, FJ | 1 |
| Argüelles, CF | 1 |
| Villalón, CM | 3 |
| Granados-Soto, V | 1 |
| Smith, ML | 1 |
| McGuire, B | 2 |
| Tarash, I | 2 |
| Evans, CJ | 1 |
| Charles, A | 2 |
| Jansen-Olesen, I | 1 |
| Tfelt-Hansen, P | 1 |
| Green, AL | 1 |
| Gu, P | 1 |
| De Felice, M | 1 |
| Dodick, D | 1 |
| Ossipov, MH | 2 |
| Cheng, LH | 1 |
| Wu, PC | 1 |
| Liu, SC | 1 |
| Chiu, FS | 1 |
| Chu, YH | 1 |
| Chang, YN | 1 |
| Wang, HW | 1 |
| Tomić, MA | 1 |
| Pecikoza, UB | 1 |
| Micov, AM | 1 |
| Popović, BV | 1 |
| Stepanović-Petrović, RM | 1 |
| Hansraj, GP | 1 |
| Singh, SK | 1 |
| Kumar, P | 1 |
| Farkas, B | 1 |
| Kardos, P | 1 |
| Orosz, S | 1 |
| Tarnawa, I | 1 |
| Csekő, C | 1 |
| Lévay, G | 1 |
| Farkas, S | 1 |
| Lendvai, B | 1 |
| Kovács, P | 1 |
| Daiutolo, BV | 1 |
| Tyburski, A | 1 |
| Clark, SW | 1 |
| Elliott, MB | 1 |
| Ferrari, LF | 1 |
| Levine, JD | 1 |
| Green, PG | 1 |
| Sufka, KJ | 1 |
| Staszko, SM | 1 |
| Johnson, AP | 1 |
| Davis, ME | 1 |
| Davis, RE | 1 |
| Smitherman, TA | 1 |
| Sant'Ana, AB | 1 |
| Weffort, LF | 1 |
| de Oliveira Sergio, T | 1 |
| Gomes, RC | 1 |
| Frias, AT | 1 |
| Matthiesen, M | 1 |
| Vilela-Costa, HH | 1 |
| Yamashita, PS | 1 |
| Vasconcelos, AT | 1 |
| de Bortoli, V | 1 |
| Del-Ben, CM | 1 |
| Zangrossi, H | 1 |
| Jones, MG | 1 |
| Andreou, AP | 1 |
| McMahon, SB | 1 |
| Spanswick, D | 1 |
| Bree, D | 1 |
| Levy, D | 1 |
| Kandasamy, R | 1 |
| Lee, AT | 1 |
| Morgan, MM | 1 |
| Kurul, SH | 1 |
| Demirpence, S | 1 |
| Kiray, M | 1 |
| Tugyan, K | 1 |
| Yilmaz, O | 1 |
| Kose, G | 1 |
| Vera-Portocarrero, LP | 1 |
| King, T | 1 |
| Lynch, JJ | 1 |
| Stump, GL | 1 |
| Kane, SA | 1 |
| Regan, CP | 1 |
| Ghelardini, C | 2 |
| Galeotti, N | 2 |
| Vivoli, E | 1 |
| Grazioli, I | 2 |
| Uslenghi, C | 2 |
| Kayser, V | 1 |
| Aubel, B | 1 |
| Hamon, M | 1 |
| Bourgoin, S | 1 |
| De Salvatore, G | 1 |
| De Salvia, MA | 1 |
| Piepoli, AL | 1 |
| Natale, L | 1 |
| Porro, C | 1 |
| Nacci, C | 1 |
| Mitolo, CI | 1 |
| Mitolo-Chieppa, D | 1 |
| Schuh-Hofer, S | 1 |
| Boehnke, C | 1 |
| Reuter, U | 1 |
| Siekmann, W | 1 |
| Lindauer, U | 1 |
| Arnold, G | 1 |
| Dirnagl, U | 1 |
| Burstein, R | 1 |
| Jakubowski, M | 1 |
| Moro, E | 1 |
| Crema, F | 1 |
| De Ponti, F | 1 |
| Frigo, G | 1 |
| Ottani, A | 1 |
| Ferraris, E | 1 |
| Giuliani, D | 1 |
| Mioni, C | 1 |
| Bertolini, A | 1 |
| Sternieri, E | 1 |
| Ferrari, A | 1 |
| Centurión, D | 1 |
| Valdivia, LF | 1 |
| de Vries, P | 2 |
| Saxena, PR | 3 |
| Gupta, S | 1 |
| Akerman, S | 1 |
| van den Maagdenberg, AM | 1 |
| Goadsby, PJ | 2 |
| van den Brink, AM | 1 |
| Huang, Z | 1 |
| Byun, B | 1 |
| Matsubara, T | 1 |
| Moskowitz, MA | 2 |
| Phebus, LA | 1 |
| Stengel, PW | 1 |
| Lobb, KL | 1 |
| Nixon, JA | 1 |
| Hipskind, PA | 1 |
| Connor, HE | 1 |
| Feniuk, W | 1 |
| Beattie, DT | 1 |
| North, PC | 1 |
| Oxford, AW | 1 |
| Saynor, DA | 1 |
| Humphrey, PP | 1 |
| Knyihár-Csillik, E | 2 |
| Tajti, J | 2 |
| Samsam, M | 1 |
| Sáry, G | 1 |
| Slezák, S | 1 |
| Vécsei, L | 2 |
| Petty, MA | 1 |
| Elands, J | 1 |
| Johnson, MP | 1 |
| Linnik, MD | 1 |
| Hamel, E | 1 |
| Lee, WS | 1 |
| McCarty, DR | 1 |
| Hibert, M | 1 |
| Baron, BM | 1 |
| McCall, RB | 1 |
| Hoskin, KL | 1 |
| Csillik, AE | 1 |
| Chadaide, Z | 1 |
| Mihály, A | 1 |
| Bingham, S | 1 |
| Davey, PT | 1 |
| Sammons, M | 1 |
| Raval, P | 1 |
| Overend, P | 1 |
| Parsons, AA | 1 |
| Limmroth, V | 1 |
| Katsarava, Z | 1 |
| Liedert, B | 1 |
| Guehring, H | 1 |
| Schmitz, K | 1 |
| Diener, HC | 1 |
| Michel, MC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Single-Center, Double-Blind, Parallel, Sham-Controlled Study of Gammacore Sapphire (Non-Invasive Vagus Nerve Stimulator) for the Acute and Preventive Treatment of Post-Traumatic Headache (GAP-PTH)[NCT04071743] | 0 participants (Actual) | Interventional | 2020-01-01 | Withdrawn (stopped due to Primary Investigator left UT Southwestern and was not replaced.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for sumatriptan and Disease Models, Animal
| Article | Year |
|---|---|
Animal migraine models for drug development: status and future perspectives.
Topics: Animals; Animals, Genetically Modified; Disease Models, Animal; Drug Discovery; Forecasting; Humans; | 2013 |
Triptans and gastric accommodation: pharmacological and therapeutic aspects.
Topics: Animals; Disease Models, Animal; Dyspepsia; Gastric Acidity Determination; Gastric Emptying; Humans; | 2004 |
Migraine: pathophysiology, pharmacology, treatment and future trends.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; History, 17th Century; History, 19th Cent | 2003 |
Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy.
Topics: Animals; Disease Models, Animal; Forecasting; Headache; Humans; Migraine Disorders; Models, Biologic | 1999 |
55 other studies available for sumatriptan and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Assessment of Sumatriptan on Sepsis-Induced Kidney injury in the Cecal Ligation and Puncture Mice Model.
Topics: Animals; Cytokines; Disease Models, Animal; Kidney; Ligation; Male; Mice; Mice, Inbred C57BL; Punctu | 2022 |
Neuroprotective effects of Lasmiditan and Sumatriptan in an experimental model of post-stroke seizure in mice: Higher effects with concurrent opioid receptors or K
Topics: Adenosine Triphosphate; Animals; Anticonvulsants; bcl-2-Associated X Protein; Benzamides; Disease Mo | 2022 |
PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine.
Topics: Animals; Calcitonin Gene-Related Peptide; Cromakalim; Disease Models, Animal; Drug Hypersensitivity; | 2022 |
PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine.
Topics: Animals; Calcitonin Gene-Related Peptide; Cromakalim; Disease Models, Animal; Drug Hypersensitivity; | 2022 |
PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine.
Topics: Animals; Calcitonin Gene-Related Peptide; Cromakalim; Disease Models, Animal; Drug Hypersensitivity; | 2022 |
PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine.
Topics: Animals; Calcitonin Gene-Related Peptide; Cromakalim; Disease Models, Animal; Drug Hypersensitivity; | 2022 |
Inhibition of ovalbumin-induced allergic rhinitis by sumatriptan through the nitric oxide pathway in mice.
Topics: Animals; Disease Models, Animal; Female; Mice; Mice, Inbred BALB C; Nitric Oxide; Nitric Oxide Synth | 2019 |
Functional NHE1 expression is critical to blood brain barrier integrity and sumatriptan blood to brain uptake.
Topics: Animals; Blood-Brain Barrier; Brain; Central Nervous System; Cortical Spreading Depression; Disease | 2020 |
Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache.
Topics: Analgesics; Animals; Benzamides; Central Nervous System Sensitization; Disease Models, Animal; Heada | 2020 |
Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache.
Topics: Analgesics; Animals; Central Nervous System Sensitization; Disease Models, Animal; Female; Headache | 2020 |
A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.
Topics: Animals; Calcitonin Gene-Related Peptide; Disease Models, Animal; Female; Hyperalgesia; Male; Mice; | 2021 |
Recurrent administration of the nitric oxide donor, isosorbide dinitrate, induces a persistent cephalic cutaneous hypersensitivity: A model for migraine progression.
Topics: Animals; Central Nervous System Sensitization; Dipeptides; Disease Models, Animal; Hyperalgesia; Iso | 2018 |
Pharmacological evidence of involvement of nitric oxide pathway in anti-pruritic effects of sumatriptan in chloroquine-induced scratching in mice.
Topics: Animals; Antipruritics; Behavior, Animal; Chloroquine; Disease Models, Animal; Dose-Response Relatio | 2018 |
Soluble guanylyl cyclase is a critical regulator of migraine-associated pain.
Topics: Adrenergic beta-Antagonists; Allosteric Regulation; Animals; Anticonvulsants; Calcitonin Gene-Relate | 2018 |
Induction of chronic migraine phenotypes in a rat model after environmental irritant exposure.
Topics: Acrolein; Analysis of Variance; Animals; Chronic Disease; Disease Models, Animal; Exploratory Behavi | 2018 |
Attenuation of serotonin-induced itch by sumatriptan: possible involvement of endogenous opioids.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Humans; Injections, Intradermal; Male; M | 2018 |
The effect of intravenous administration of liposomal curcumin in addition to sumatriptan treatment in an experimental migraine model in rats.
Topics: Administration, Intravenous; Animals; Curcumin; Disease Models, Animal; Liposomes; Male; Malondialde | 2018 |
The protective effects of sumatriptan on vincristine - induced peripheral neuropathy in a rat model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Male; Neuroprotective Agents; Pa | 2018 |
Peripherally administered calcitonin gene-related peptide induces spontaneous pain in mice: implications for migraine.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies; Calcitonin Gene-Related Peptide; Disea | 2018 |
The use of focused ultrasound for the treatment of cutaneous allodynia associated with chronic migraine.
Topics: Animals; Disease Models, Animal; Hyperalgesia; Male; Migraine Disorders; Pain Threshold; Peripheral | 2018 |
Delta opioid receptor agonists are effective for multiple types of headache disorders.
Topics: Animals; Benzamides; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Headache Diso | 2019 |
Role of 5-HT₁B/₁D receptors in the reduction of formalin-induced nociception and secondary allodynia/hyperalgesia produced by antimigraine drugs in rats.
Topics: Acute Pain; Animals; Biphenyl Compounds; Chronic Pain; Dihydroergotamine; Disease Models, Animal; Dr | 2013 |
Characterization of a novel model of chronic migraine.
Topics: Animals; Chronic Disease; Disease Models, Animal; Female; Freund's Adjuvant; Hyperalgesia; Male; Mic | 2014 |
Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache.
Topics: Afferent Pathways; Animals; Cortical Spreading Depression; Disease Models, Animal; Electric Stimulat | 2014 |
Effects of sumatriptan nasal spray (Imigran) on isolated rat's tracheal smooth muscle.
Topics: Animals; Asthma; Disease Models, Animal; Electric Stimulation; Muscle Contraction; Muscle, Smooth; N | 2015 |
The effects of levetiracetam, sumatriptan, and caffeine in a rat model of trigeminal pain: interactions in 2-component combinations.
Topics: Analgesics; Animals; Behavior, Animal; Caffeine; Disease Models, Animal; Dose-Response Relationship, | 2015 |
Sumatriptan succinate loaded chitosan solid lipid nanoparticles for enhanced anti-migraine potential.
Topics: Animals; Behavior, Animal; Brain; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Chi | 2015 |
Predictive validity of endpoints used in electrophysiological modelling of migraine in the trigeminovascular system.
Topics: Action Potentials; Animals; Blood Pressure; Disease Models, Animal; Electric Stimulation; Fructose; | 2015 |
Trigeminal Pain Molecules, Allodynia, and Photosensitivity Are Pharmacologically and Genetically Modulated in a Model of Traumatic Brain Injury.
Topics: Animals; Brain Injuries, Traumatic; Calcitonin Gene-Related Peptide; Disease Models, Animal; Hyperal | 2016 |
The effects of acute and preventive migraine therapies in a mouse model of chronic migraine.
Topics: Acute Disease; Amiloride; Animals; Anticonvulsants; Disease Models, Animal; Drug Evaluation, Preclin | 2016 |
Mechanisms mediating nitroglycerin-induced delayed-onset hyperalgesia in the rat.
Topics: Animals; Disease Models, Animal; Endothelial Cells; Female; Hyperalgesia; Male; Mast Cells; Neutroph | 2016 |
Clinically relevant behavioral endpoints in a recurrent nitroglycerin migraine model in rats.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Male; Migraine Disorders; Motor Activity; Nitrogl | 2016 |
Panic-modulating effects of alprazolam, moclobemide and sumatriptan in the rat elevated T-maze.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Brain; Disease Models, Animal; Escape Reaction; Explorator | 2016 |
Pharmacology of reflex blinks in the rat: a novel model for headache research.
Topics: Animals; Blinking; Disease Models, Animal; Electromyography; Male; Migraine Disorders; Nitric Oxide | 2016 |
Development of CGRP-dependent pain and headache related behaviours in a rat model of concussion: Implications for mechanisms of post-traumatic headache.
Topics: Analgesics; Animals; Antibodies, Monoclonal; Behavior, Animal; Brain Concussion; Disease Models, Ani | 2018 |
Depression of home cage wheel running: a reliable and clinically relevant method to assess migraine pain in rats.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Female; Isothiocyanates; Migraine Disorders; Rats | 2017 |
Investigation of the immunoreactivities of NOS enzymes and the effect of sumatriptan in adolescent rats using an experimental model of migraine.
Topics: Analysis of Variance; Animals; Brain; Disease Models, Animal; Male; Migraine Disorders; Nitric Oxide | 2008 |
Reversal of inflammatory and noninflammatory visceral pain by central or peripheral actions of sumatriptan.
Topics: Abdominal Pain; Animals; Behavior, Animal; Butyrates; Disease Models, Animal; Immunosuppressive Agen | 2008 |
The prototype serotonin 5-HT 1B/1D agonist sumatriptan increases the severity of myocardial ischemia during atrial pacing in dogs with coronary artery stenosis.
Topics: Animals; Cardiac Pacing, Artificial; Coronary Circulation; Coronary Stenosis; Disease Models, Animal | 2009 |
The central analgesia induced by antimigraine drugs is independent from Gi proteins: superiority of a fixed combination of indomethacin, prochlorperazine and caffeine, compared to sumatriptan, in an in vivo model.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Caffeine; Central Nervous Syste | 2009 |
The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain.
Topics: Animals; Dihydroergotamine; Disease Models, Animal; Male; Migraine Disorders; Oxazolidinones; Pain; | 2002 |
Effects of in vivo treatment with interleukins 1beta and 6 on rat mesenteric vascular bed reactivity.
Topics: Acetylcholine; Animals; Arginine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Syn | 2003 |
A fluorescence-based method to assess plasma protein extravasation in rat dura mater using confocal laser scanning microscopy.
Topics: Animals; Biological Assay; Blood Proteins; Disease Models, Animal; Dose-Response Relationship, Drug; | 2003 |
Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization.
Topics: Animals; Brain Mapping; Disease Models, Animal; Electrophysiology; Male; Migraine Disorders; Neurons | 2004 |
Effect of sumatriptan in different models of pain in rats.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Pain Measurement; Rats; Rat | 2004 |
Indomethacin, alone and combined with prochlorperazine and caffeine, but not sumatriptan, abolishes peripheral and central sensitization in in vivo models of migraine.
Topics: Animals; Caffeine; Disease Models, Animal; Drug Therapy, Combination; Indomethacin; Male; Mice; Migr | 2004 |
Intravital microscopy on a closed cranial window in mice: a model to study trigeminovascular mechanisms involved in migraine.
Topics: Animals; Arteries; Calcitonin Gene-Related Peptide; Capsaicin; Disease Models, Animal; Dura Mater; E | 2006 |
Time-dependent blockade of neurogenic plasma extravasation in dura mater by 5-HT1B/D agonists and endopeptidase 24.11.
Topics: Animals; Capsaicin; Disease Models, Animal; Dura Mater; Electric Stimulation; Extravasation of Diagn | 1993 |
The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Dura Mater; Electric Stimulation; | 1997 |
Naratriptan: biological profile in animal models relevant to migraine.
Topics: Animals; Basilar Artery; Cerebrovascular Circulation; Disease Models, Animal; Dogs; Dose-Response Re | 1997 |
Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model.
Topics: Animals; Blood-Brain Barrier; Calcitonin Gene-Related Peptide; Disease Models, Animal; Dura Mater; E | 1997 |
The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine.
Topics: Animals; Binding, Competitive; Cats; Cerebral Arteries; Cyclic AMP; Disease Models, Animal; Guinea P | 1997 |
Trigeminal ganglion elicited increases in nucleus trigeminal caudalis blood flow: a novel migraine model.
Topics: Animals; Cats; Disease Models, Animal; Electric Stimulation; Electrophysiology; Female; Male; Migrai | 1997 |
Differential effects of low dose CP122,288 and eletriptan on fos expression due to stimulation of the superior sagittal sinus in cat.
Topics: Animals; Cats; Cranial Sinuses; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evalu | 1999 |
Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model.
Topics: Animals; Axons; Brain; Calcitonin Gene-Related Peptide; Disease Models, Animal; Dura Mater; Female; | 2000 |
Inhibition of inflammation-induced thermal hypersensitivity by sumatriptan through activation of 5-HT(1B/1D) receptors.
Topics: Analysis of Variance; Animals; Carrageenan; Discriminant Analysis; Disease Models, Animal; Female; H | 2001 |
An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calcitonin Gene-Related Peptide; Disease | 2001 |